Table 3.
Treatment-related adverse events in all treated patients (n = 50).
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Any grade | |
|---|---|---|---|---|---|
| Number of patients (%) | 10 (20.0) | 20 (40.0) | 8(16.0) | 4 (8.0) | 42 (84.0) |
| Number of events (%) | 60 | 44 | 18 | 7 | 129 |
| Hematological | |||||
| Neutropenia | 3 (6.0) | 4 (8.0) | 5 (10.0) | 3 (6.0) | 15 (30.0) |
| Leucopenia | 4 (8.0) | 12 (24.0) | 6 (12.0) | 3 (6.0) | 25 (50.0) |
| Anemia | 10 (20.0) | 7 (14.0) | 1 (2.0) | 0 | 18 (36.0) |
| Thrombocytopenia | 4 (8.0) | 5 (10.0) | 0 | 1 (2.0) | 10 (20.0) |
| Non-hematological | |||||
| Appetite decrease | 8 (16.0) | 2 (4.0) | 0 | 0 | 10 (20.0) |
| Nausea and vomiting | 4 (8.0) | 1 (2.0) | 0 | 0 | 5 (10.0) |
| Diarrhea | 3 (6.0) | 1 (2.0) | 5 (10.0) | 0 | 9 (18.0) |
| Abdominal distention | 11 (22.0) | 4 (8.0) | 0 | 0 | 15 (30.0) |
| Neurotoxicity | 3 (6.0) | 0 | 0 | 0 | 3 (6.0) |
| Venous thrombosis | 0 | 1 (2.0) | 0 | 0 | 1 (2.0) |
| Asthenia | 9 (18.0) | 4 (8.0) | 1 (2.0) | 0 | 14 (28.0) |
| Alopecia | 1 (2.0) | 1 (2.0) | 0 | 0 | 2 (4.0) |
| Renal function abnormal | 0 | 2 (4.0) | 0 | 0 | 2 (4.0) |